Today: 7 February 2026
Subscribe
Browse Category

NYSE:IBM News 4 February 2026 - 7 February 2026

Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

Confluent shares closed at $30.57 Friday, 43 cents below IBM’s $31-per-share cash offer, ahead of key events next week. The company will report earnings Feb. 11 without a call or outlook, and shareholders vote on the merger Feb. 12. Confluent disclosed 17 demand letters and two lawsuits over proxy disclosures but denies wrongdoing. The IBM deal values Confluent at $11 billion.
7 February 2026
··
Confluent stock stays pinned below IBM’s $31 bid as vote nears and SEC filing flags lawsuits

Confluent stock stays pinned below IBM’s $31 bid as vote nears and SEC filing flags lawsuits

Confluent shares traded near $30.36 premarket Friday, just below IBM’s $31-per-share cash offer, after the company filed new merger disclosures with the SEC in response to shareholder demand letters and lawsuits. Confluent will report earnings Feb. 11 but will not hold a call or forecast while the IBM deal remains pending. The shareholder vote is set for Feb. 12.
6 February 2026
···
Confluent stock (CFLT) sits under IBM’s $31 bid after fresh merger filing flags shareholder lawsuits

Confluent stock (CFLT) sits under IBM’s $31 bid after fresh merger filing flags shareholder lawsuits

Confluent shares traded at $30.36 after hours Thursday, just below IBM’s $31-per-share cash offer. The company filed additional merger disclosures following 17 shareholder demand letters and two lawsuits alleging proxy omissions. A shareholder vote on the IBM acquisition is set for Feb. 12. The stock’s narrow spread reflects market focus on deal completion risk.
6 February 2026
···
Confluent stock holds near $31 IBM bid as new SEC filing details shareholder suits, Feb. 12 vote

Confluent stock holds near $31 IBM bid as new SEC filing details shareholder suits, Feb. 12 vote

Confluent shares edged up 0.1% to $30.37 Thursday after the company disclosed new details on shareholder litigation tied to its pending $11 billion IBM acquisition. The stock traded about 2% below IBM’s $31-per-share offer as investors watched for the Feb. 12 shareholder vote and Confluent’s earnings report on Feb. 11.
5 February 2026
····
IBM stock slides again as AI disruption fears grip software; Confluent vote nears

IBM stock slides again as AI disruption fears grip software; Confluent vote nears

IBM shares fell 1.8% to $289.05 Wednesday, extending an 8% slide since Monday amid a global software selloff tied to AI disruption fears. Confluent, which IBM plans to acquire, disclosed lawsuits and shareholder demands over its merger proxy, but said it will issue supplemental disclosures. IBM declared a $1.68 per share dividend, payable March 10. Confluent shareholders will vote on the deal February 12.
5 February 2026
····
Confluent stock price today: CFLT stays just under IBM’s $31 offer as February deadlines near

Confluent stock price today: CFLT stays just under IBM’s $31 offer as February deadlines near

Confluent shares traded at $30.42 Wednesday, about 2% below IBM’s $31-per-share cash offer, as investors await a February 12 shareholder vote on the $11 billion deal. The U.S. antitrust waiting period expired January 12, but the merger still needs shareholder and further regulatory approval. Confluent will report earnings February 11 without a call or outlook. Trading volume surged to 53 million shares ahead of key dates.
4 February 2026
···
Confluent stock hovers below IBM’s $31 bid as key vote, results near

Confluent stock hovers below IBM’s $31 bid as key vote, results near

Confluent shares closed at $30.34 on Wednesday, about 2% below IBM’s $31-per-share cash offer, as software stocks fell and IBM dropped 4%. Heavy trading volume followed ahead of Confluent’s earnings report on Feb. 11 and a shareholder vote on Feb. 12. The spread to IBM’s bid now signals deal risk and timing. U.S. antitrust review ended Jan. 12, but other approvals remain pending.
4 February 2026
···
IBM stock price slides again as AI disruption fears hit software, IT services

IBM stock price slides again as AI disruption fears hit software, IT services

IBM shares fell $9.19, or 3.1%, to $285.12 Wednesday amid heightened concerns over AI competition and a weak outlook from Gartner. The selloff followed Anthropic’s launch of new AI tools and a sharp drop in Gartner’s consulting revenue. Investors are watching IBM’s upcoming earnings and February dividend record date. U.S. equities also declined Tuesday as tech sector worries spread.
4 February 2026
···
Accenture stock price: ACN steadies premarket after Tuesday’s rout as AI disruption fears linger

Accenture stock price: ACN steadies premarket after Tuesday’s rout as AI disruption fears linger

Accenture shares fell 0.2% to $240.68 premarket Wednesday after plunging 9.59% Tuesday, as investors reassess software and IT services stocks on fears AI agents could disrupt business models. The S&P software and services index has dropped over 12% in five sessions. CEO Julie Sweet filed to sell 5,500 shares. Cognizant forecast full-year revenue above estimates, citing strong AI demand.
4 February 2026
······
IBM stock price slides after-hours as AI disruption fears rattle software and consulting shares

IBM stock price slides after-hours as AI disruption fears rattle software and consulting shares

IBM shares fell 6.5% to $294.31 in after-hours trading Tuesday, erasing about $20 from the session’s high. The drop followed a broader selloff in software and services stocks after Anthropic launched new AI tools. Trading volume reached 11.5 million shares. IBM’s dividend record date is Feb. 10, with preliminary Q1 earnings due April 22.
4 February 2026
····
1 2 3 … 10

Stock Market Today

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

7 February 2026
New York, February 7, 2026, 05:48 EST — Market closed Pfizer Inc (PFE) shares ended Friday up 2.8% at $27.22, after trading between $26.52 and $27.37. About 50.7 million shares changed hands. (Yahoo Finance) The stock’s late-week lift comes with a key regulatory clock running: the FDA granted priority review for Pfizer’s supplemental filing to broaden use of its hemophilia drug Hympavzi, with a target decision deadline in the second quarter. Priority review shortens the agency’s standard review timeline by four months. “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors,”
Go toTop